Navigation Links
Sublingual immunotherapy for inhalant allergies deserves deeper consideration
Date:4/29/2009

Alexandria, VA Sublingual immunotherapy for the treatment of allergy symptoms caused by a wide variety of environmental inhalants has been effectively used in Europe. It should be employed to further treatment of allergies in the United States, where allergic symptoms are largely undertreated, according to an invited article in the April 2009 issue of Otolaryngology-Head and Neck Surgery. A response to the article, published in the same journal issue, expresses cautious optimism, but calls for additional research.

Sublingual immunotherapy (SLIT) involves the administering of an allergen solution under the tongue, which in time reduces the patient's sensitivity to those allergens. The more prevalent alternative is subcutaneous immunotherapy, usually administered through an injection.

The authors of the invited article note that despite allergic symptoms contributing heavily to poor quality of life, high socioeconomic costs, and increased health issues, these syndromes remain underdiagnosed and undertreated. The authors attribute this to a public attitude that trivializes allergic conditions, along with patients' general dissatisfaction with the conventional pharmacy-based ways of treating allergic conditions. They conclude that the extensive implementation of SLIT treatment in Europe has proven to overcome these shortcomings in reaching patients, and the treatment is supported with significant literature documenting its efficacy, along with extensive clinical experience.

In a response to the invited article, AAO-HNSF Board of Directors member John H. Krouse, MD, PhD, recognizes the promising data associated with SLIT treatment, but urges caution until several issues can be addressed. Specifically, Dr. Krouse offers five areas of concern with SLIT treatment: patient selection; pattern of sensitization; dosing, preparation, and delivery; safety; and the financial cost of therapy. He concludes by noting the existence of a gap in allergy m
'/>"/>

Contact: Matt Daigle
newsroom@entnet.org
703-535-3754
American Academy of Otolaryngology -- Head and Neck Surgery
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. A Few Shots Away: Immunotherapy May Relieve Allergy Symptoms
2. Oral Allergy Immunotherapy Helps Control Asthma
3. Radioimmunotherapy After Chemo Safe for Common Lymphoma
4. Immunotherapy: enlisting the immune system to fight cancer
5. FDA Says, Wait To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy
6. Dangerous Side Effect Found in Cancer Immunotherapy Research
7. Latest research on allergies: Specific immunotherapy can help
8. OHSU Cancer Institute researcher: radiation, immunotherapy gives greater effectiveness
9. Educational Symposium to Present Panel Discussion on Melanoma Treatments and Immunotherapy
10. Towards improved immunotherapy
11. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... WV (PRWEB) June 19, 2013 The ... individual used the sauna but the overall experience for ... to be positive health-wise. , Mr Mouw, whose Virgina-based ... to the Society’s statement by saying that the type ... learned of a number of counterfeit imitations which frankly, ...
(Date:6/19/2013)... June 19, 2013 Researchers from the ... demonstrated several new studies at ENDO 2013, The ... June 15-18 in San Francisco.     , Mount Sinai researchers ... the role of prostastic acid phosphatase (PAP) in Prostate ... stimulate the thyroid gland; revealed the prevalence of primary ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 CCA ... of Dr. John Baxter to Vice President, Health Services, ... as Director, Mental Health Services for CCA. He ... an honor and great privilege to lead CCA's dedicated ... unique opportunity to serve society and our partners as ...
(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... 2013 Citi Bike has come to New York ... David Perna to know for sure how many patients will choose ... they’ll have the option. In fact, he’s happy about anything ... also make it more convenient for them to visit his office ... of Complimentary Alternative Medicine at Back and Body Medical and an ...
Breaking Medicine News(10 mins):Health News:Health Benefits of Saunas Only Viable with Properly Constructed Models, Warns Manufacturer 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 3Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 4Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 5Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 6Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 7Health News:CCA Names Dr. John Baxter Vice President, Health Services 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3
... traumatic brain injuries occur, a speedy diagnosis followed by ... and death. A research team, led by Jason D. ... at the U.S. National Institutes of Health, has created ... such as hematomas, which occur when blood vessels become ...
... have been shown to have higher levels of education ... physically active, and have other characteristics that are associated ... been inconsistent in showing that, after adjustment for all ... of cardiovascular disease and mortality than do consumers of ...
... infant survival rates in 19th -Century Montreal in two ... McGill University. Mother,s milk protected vulnerable infants from food ... the arrival of more siblings and that improved the ... Published in the journal Population Studies , ...
... patterns of emergency care for an entire state has ... Indiana over a three-year period were by patients who ... conventional wisdom that patients are tightly bound to health ... The Regenstrief Institute study, "All Health Care Is ...
... Western Reserve University School of Medicine received a $6.75 ... Diabetes and Digestive and Kidney Diseases (NIDDK) to study ... (IBD). For years, scientists have focused their attention on ... in the cause of Crohn,s disease, a chronic debilitating ...
... they,re thought to be more fearful and feel threatened ... Aviv University shows that the anxious may not be hypersensitive ... enough. As part of a study on how the ... a Ph.D. candidate in TAU,s School of Psychological Sciences and ...
Cached Medicine News:Health News:New device for rapid, mobile detection of brain injury 2Health News:Breastfeeding saved babies in 19th- Century Montreal 2Health News:Breastfeeding saved babies in 19th- Century Montreal 3Health News:First study of emergency care for an entire state finds care isn't always local 2Health News:$6.75 million awarded to Case Western Reserve to study IBD 2Health News:Are the anxious oblivious? 2
(Date:6/19/2013)... Pharmacyclics, Inc. (the "Company") (Nasdaq: ... Journal of Medicine ( NEJM ) published results ... Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients with ... ibrutinib may be effective and generally well-tolerated in patients ... separate study examining the safety and efficacy of ibrutinib ...
(Date:6/19/2013)... BRAINTREE, Mass. , June 19, 2013 /PRNewswire/ ... announced several important developments in the pursuit of ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) , ... SANM ) for the future production of medical ... , Massachusetts. Sanmina is a leading global provider of ...
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- Robert M. Bernstein, M.D., ... procedures and founder of Bernstein Medical – Center ... Doctors, issue of New York Magazine for the ... ) Dr. Bernstein earned his ... reputation as world-renowned hair restoration physician, through a ...
Breaking Medicine Technology:Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3
... 27 Kinex Pharmaceuticals will present results from a Phase ... Meeting in Orlando, on May 29, 2009. The study ... (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, ... "Results of a phase I trial of KX2-391, a novel ...
... Administered in Dual Cord Blood Transplant for Hematologic MalignancyLA JOLLA, ... announced today that the first patient has been treated ... molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem ... pathways that guide cell fate. The study, which is ...
Cached Medicine Technology:Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 2Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 4
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Medicine Products: